The latest updates on gastric and esophageal cancers focus on greater use of biomarkers, next-generation sequencing (NGS), and immunotherapies.
The latest updates on gastric and esophageal cancers focus on greater use of biomarkers, next-generation sequencing (NGS), and immunotherapies. These updates were presented during the National Comprehensive Cancer Network 2021 Virtual Annual Conference by Crystal S. Denlinger, MD, Fox Chase Cancer Center, Philadelphia; Kristina A. Makowskyj, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison; and Mary F. Mulcahy, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.1
“This is an exciting time to be a medical oncologist who treats not only [patients with] gastrointestinal cancers but gastroesophageal cancer. I think it’s safe to say that biomarkers are going to be key for categorizing our patients,” said Denlinger, who is chief of the Division of Gastrointestinal Medical Oncology, director of the Survivorship Program, deputy director of the Early Clinical Drug Development Phase 1 Program, and an associate professor in the Department of Hematology/Oncology at Fox Chase. “The bare minimum that needs to be ordered at a new diagnosis includes microsatellite status, HER2 status, and PD-L1 status.”
Biomarker testing can be performed on formalinfixed, paraffin embedded tissue; however, these tissues must be held for a minimum of 10 years, unless they are being exhausted for diagnostic purposes or clinical trial enrollment. “As such, we’re always able to go back to the tissue that was obtained from that patient should new biomarkers arise,” noted Matkowskyj, who is director of Translational Science BioCore and associate director of the Translational Research Initiatives Laboratory in the Department of Pathology and Laboratory Medicine at UWCCC.
Matkowskyj, who is also an associate professor in the Department of Pathology and Laboratory Medicine at the University of Wisconsin School of Medicine and Public Health and staff pathologist at William S. Middleton Memorial Veterans Hospital, added that it is important to ensure that tissue is being sent to a Clinical Laboratory Improvement Amendment–approved laboratory for testing. Biomarkers that need to be tested include HER2 per immunohistochemistry (IHC), microsatellite instability (MSI) via a polymerase chain reaction (PCR) test or mismatch repair protein expression via IHC, and PD-L1 expression via IHC.
Although NGS enables the evaluation of several mutations at once, as well as other molecular effects such as amplification, deletions, tumor mutational burden [TMB], and MSI status, it is not without limitations. As such, “testing should always be first performed by those gold-standard methods [of IHC and in situ hybridization],” noted Matkowskyj. If abundant tissue is available, the initial tests can be performed, and they can be followed by NGS.
Full NGS profiling may be appropriate when limited tissue is available or biopsy is not possible. However, Denlinger warned that with limited tumor samples, it is important to be careful and consider whether full profiling should be used versus individual biomarkers alone.
“New within the guidelines is that all gastric cancers should now be tested for MSI up front at the time of diagnosis,” noted Matkowskyj; this can be done through the use of IHC or PCR.
Immune checkpoint inhibitors can now be considered for use in combination with platinum-fluoropyrimidine in the frontline treatment of patients with gastroesophageal cancer who have a high combined positive score (CPS). The update is based in part on data from the phase 3 CheckMate 649 trial (NCT02872116).2
In the study, previously untreated patients with unresectable, advanced, or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma with no known HER2-positive status and an ECOG performance status of 0 or 1 were randomized 1:1:1 to nivolumab plus ipilimumab (Yervoy), nivolumab plus XELOX (capecitabine [Xeloda] and oxaliplatin) or FOLFOX (folinic acid, fluorouracil, and oxaliplatin) per provider decision, or XELOX or FOLFOX.
“We’re just going to look at the randomized study of nivolumab plus chemotherapy [n = 789] vs chemotherapy alone [n = 792],” noted Mulcahy, a professor in the Division of Hematology and Oncology, Department of Medicine at Northwestern University and director of the Gastrointestinal and Oncologic Surgery Program at Robert H. Lurie Comprehensive Cancer Center. “Notably, this did not include the squamous cell population; this is all adenocarcinomas.”
The dual primary end points of the trial were overall survival (OS) and progression-free survival (PFS) for patients with a PD-L1 CPS of greater than 5%. Results indicated that nivolumab plus chemotherapy significantly improved median OS over that of the chemotherapy arm. The median OS was 14.4 months (95% CI, 13.1-16.2) in the investigative arm versus 11.1 months (95% CI, 10.0-12.1) in the control arm (HR, 0.71; 95% CI, 0.59-0.86; P <.0001).
"What’s interesting in this study is that it just so happens that more than 60% of patients had a CPS of greater than 5, and more than 80% had a CPS of greater than 1, so this was somewhat of an enriched population for PD-L1 expression,” Mulcahy said.
In patients who had a PD-L1 CPS of 1 or greater, the median OS still favored the nivolumab regimen over chemotherapy alone, with a median OS of 14.0 months (95% CI, 12.6-15.0) versus 11.3 months (95% CI, 10.6-12.3), respectively (HR, 0.77; 95% CI, 0.64-0.92; P =.0001). In all randomized patients, the HR was 0.80 (95% CI, 0.68-0.94; P =.0002).
The nivolumab-containing regimen also resulted in an improvement in objective response rate (ORR) over chemotherapy alone, at 60% (95% CI, 55%-65%) versus 45% (95%, 40%- 50%), respectively (P <.0001). The duration of response (DOR) was also maintained for those on the nivolumab arm, at 9.5 months versus 7.0 months for those on chemotherapy.
“Nivolumab is the first PD-1 inhibitor to demonstrate a superior response, PFS, as well as DOR, when compared with chemotherapy,” Mulcahy said. “As such, nivolumab plus chemotherapy presents a new standard-of-care firstline therapy for patients with adenocarcinoma and gastric cancer with a PD-L1 CPS of greater than or equal to 5.”
In the phase 3 KEYNOTE-590 trial (NCT03189719), treatment-naive patients with locally advanced, unresectable or metastatic esophageal adenocarcinoma, esophageal squamous cell carcinoma (ESCC), or esophagogastric junction Siewert type 1 adenocarcinoma with an ECOG performance status of 0 or 1 and measurable disease were randomized 1:1 to receive either pembrolizumab and chemotherapy with 5-fluorouracil (5-FU) and cisplatin or placebo and chemotherapy.3
"Patients enrolled to this study had esophageal adenocarcinoma or squamous cell cancer,” Mulcahy noted. “No specification about PD-L1 expression [was made]…for enrollment purposes or stratification. Another thing to point out is that the chemotherapy backbone used in this study is not commonly used for most of us in practice. Many have switched to an oxaliplatin-based therapy; it’s better tolerated,” he said.
The dual primary end points of the trial included OS and PFS per RECIST 1.1 criteria and investigator assessment, whereas ORR per the same criteria served as the secondary end point.
Notably, 73.5% of patients on the pembrolizumab arm and 72.9% of those on the chemotherapy-alone arm had squamous histology, which is not a common histology in the United States, noted Mulcahy. About half of the patients enrolled had a PD-L1 CPS of greater than 10, “so this was a very rich population for a high PD-L1 expression,” noted Mulcahy.
The addition of pembrolizumab to the chemotherapy backbone was found to significantly improve OS in patients with a PD-L1 CPS of 10 or higher. In these patients, the median OS was 13.5 months (95% CI, 11.1-15.6) and 9.4 months (95% CI, 8.0-10.7) in the investigative and control arms, respectively (HR, 0.62; 95% CI, 0.49-0.78; P < .0001). The investigators also found that the pembrolizumab-containing regimen improved OS over chemotherapy alone in all patients (HR, 0.73; 95% CI, 0.62- 0.86; P < .0001).
A “striking difference” in OS was also observed in patients specifically with ESCC who had a PD-L1 CPS of 10 or higher. In this subset, the median OS was 13.9 months (95% CI, 11.1-17.7) in the pembrolizumab arm versus 8.8 months (95% CI, 7.8-10.5) in the chemotherapy-alone arm (HR, 0.57; 95% CI, 0.43-0.75; P < .0001).
OS in all patients with ESCC also favored the pembrolizumab-containing regimen (HR, 0.72; 95% CI, 0.60-0.88). Investigators also observed a benefit in terms of ORR and DOR with pembrolizumabchemotherapy versus chemotherapy alone. The ORRs in the investigative and control arms were 45.0% (95% CI, 39.9%-50.2%) versus 29.3% (95% CI, 24.7%-34.1%), respectively (P<.0001); the median DORs were 8.3 months and 6.0 months, respectively.
“These data support the use of pembrolizumab with chemotherapy for all [patients with] esophageal cancer and [a PD-L1] CPS of greater than 10,” said Mulcahy. “However, the most striking difference was seen in [those] with squamous cell [disease].”
“We have previously been disappointed in our second-line, HER2-directed treatment options,” admitted Denlinger. “This is clearly not the same as what has been seen in breast cancer, where HER2-directed therapy across lines of treatment has been effective.”
For instance, data from TyTAN (NCT00486954), which examined second-line paclitaxel with or without lapatinib (Tykerb) in Asian patients with HER2-amplified, advanced gastric cancer, demonstrated activity in patients with HER2 fluorescence in situ hybridization–positive IHC3+ advanced disease. However, the phase 3 trial did not significantly improve OS in the intent-to-treat population.4
Additionally, findings from the phase 2/3 GATSBY trial (NCT01641939), which evaluated second-line ado-trastuzumab emtansine (Kadcyla; T-DM1) versus physician’s choice of paclitaxel or docetaxel in those with HER2-positive advanced gastric cancer, failed to show superiority with T-DM1 over taxane treatment.5 Lastly, the phase 2 T-ACT trial (UMIN000009297), which looked at second-line paclitaxel with or without trastuzumab (Herceptin) in patients with HER2-positive advanced gastric or GEJ cancer, demonstrated that the addition of trastuzumab was not superior.6
“Up until recently, we had no data [to support] HER2-directed therapy after progression on trastuzumab and this may be due to the fact that HER2 expression can change after trastuzumab,” noted Denlinger.
Despite these challenges, the antibody-drug conjugate (ADC) trastuzumab deruxtecannxki (Enhertu) has emerged in the treatment paradigm. The drug received FDA approval in January 2021 for use in adult patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have previously received a trastuzumab-based regimen, based on data from DESTINY-Gastric01 (NCT03329690).7
“It’s an ADC that has been optimized to try and get delivery of the cytotoxic drug to the tumor cell and it has a pretty high drug to antibody ratio of 8:1,” said Denlinger. “The other neat thing about this particular drug is that the cytotoxic agent can diffuse across cell membranes to neighboring cells to create a bystander effect.”
DESTINY-Gastric01, a phase 2 trial, included 188 patients with HER2-positive advanced gastric or GEJ adenocarcinoma who had progressed on a trastuzumab-based regimen and received rimidine-platinum. Patients were randomized 2:1 to receive either the ADC (n=126) or physician’s choice of chemotherapy in the form of irinotecan (n= 55) or paclitaxel (n = 7).
Trastuzumab deruxtecan significantly improved OS over chemotherapy, at 12.5 months (95% CI, 9.6-14.3) and 8.4 months (95% CI, 6.9- 10.7), respectively (HR, 0.59; 95% CI, 0.39-0.88; P=.01). The ADC also improved PFS over chemotherapy, at 5.6 months (95% CI, 4.3-6.9) versus 3.5 months (95% CI, 2.0-4.3), respectively (HR, 0.47; 95% CI, 0.31-0.71).
Moreover, trastuzumab deruxtecan elicited an ORR of 51% (95% CI, 42%-61%) vs 14% (95% CI, 6%-26%) with chemotherapy. “For those of us who have seen a lot of gastroesophageal cancer, patients [in the third-line setting] do not typically get a response to therapy, so 51% is a very clinically meaningful number,” noted Denlinger.
Eighty-six percent of patients in the investigative arm achieved disease control vs 62% of those in the control arm.
However, the agent is not without toxicities; adverse effects can include nausea, vomiting, cytopenias, alopecia, and fatigue. Notably, the investigators found that interstitial lung disease or pneumonitis had occurred in 10% of patients, with a median time to onset of 84 days and a median time to resolution of 57 days.
“The package insert specifically states to initiate corticosteroid therapy at grade 1 and to discontinue the drug at grade 2 and use higher doses of steroids,” explained Denlinger. “This is something that really needs to be thought about because the median onset is long, approximately 3 months, and the median time to resolution is approximately 2 months. We need to ensure that we monitor for this and consider early initiation of corticosteroids if this effect is suspected.”
Single-agent ramucirumab (Cyramza) or ramucirumab in combination with paclitaxel has proved to be an effective second-line treatment option for patients with advanced gastroesophageal adenocarcinoma. In addition, an increasing number of patients are pretreated with docetaxel in the perioperative or frontline setting.
In the phase 2/3 RAMIRIS trial (NCT03081143), patients with advanced or metastatic gastroesophageal adenocarcinoma who previously received treatment with a fluoropyrimidine-platinum–containing regimen were randomized 2:1 to receive either folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab or paclitaxel plus ramucirumab.8 The trial end points included OS, ORR, disease control rate (DCR), PFS, and toxicity.
The ORR achieved with FOLFIRI-ramucirumab was 22% (n = 16/72) versus 11% (n = 4/38) with paclitaxel-ramucirumab; in docetaxel-pretreated patients, these rates were 25% (n = 12/48) and 8% (n = 2/24), respectively. The DCR rates in the FOLFIRI and paclitaxel arms were 61% (n= 44/72) and 58% (n= 21/38), respectively; in patients pretreated with docetaxel, these rates were 65% (n = 31/48) and 37% (n = 9/24), respectively.
“A larger phase 3 trial is looking at this to confirm the benefit, but certainly FOLFIRI plus ramucirumab is an option for patients in whom a taxane-based treatment option is not ideal,” said Denlinger.
Additionally, the phase 3 KEYNOTE-061 trial (NCT02370498) compared pembrolizumab with paclitaxel in patients with previously treated, advanced gastric or GEJ cancer with a PD-L1 CPS of 1 or higher.9,10 Results showed that pembrolizumab did not significantly improve OS versus paclitaxel as a second-line treatment in this population.
“This was a negative trial but there are some subpopulations in which immunotherapy might be an option. …Certainly, looking at the OS curves from the original study, the benefit of therapy seems to be greatest in the [patients with] a PD-L1 CPS of greater than 10,” noted Denlinger. “However, subset analyses from the study suggest that the population that maybe will benefit the most from it are the MSI-high (MSI-H) patients…a similar subset analysis suggested that in patients who had a high TMB, pembrolizumab performed better than paclitaxel.”
In KEYNOTE-059 (NCT02335411), investigators examined the safety and efficacy of single-agent pembrolizumab in 259 patients with previously treated advanced gastric or GEJ cancer.11 Results indicated that the ORR achieved with the immunotherapy was 11.6% (95% CI, 8.0%-16.1%), with 2.3% of patients achieving a complete response. The median DOR was 8.4 months.
Patients who had PD-L1–positive tumors fared even better with the therapy, with an ORR of 15.5% (95% CI, 10.1%-22.4%) and a median DOR of 16.3 months. Those with PD-L1 negativity still derived benefit, with an ORR of 6.4% (95% CI, 2.6%-12.8%) and a DOR of 6.9 months.
“When you look deeper into the study, you do find that those who are PD-L1 positive did have a greater response rate than those who were PD-L1 negative; this did translate to an improvement in OS,” Mulcahy noted. “I think study after study we’re finding out that those with the higher PD-L1 expression are more likely to derive benefit from it.”
In the phase 3 TAGS trial (NCT02500043), investigators set out to evaluate the efficacy and safety of trifluridine-tipiracil (TAS-102; Lonsurf) plus best supportive care (BSC) versus BSC alone in patients with heavily pretreated, metastatic gastric cancer.12,13
Results showed a significant OS benefit with TAS-102, at 5.7 months versus 3.6 months with BSC (HR, 0.69; 95% CI, 0.56-0.85; P=.00058). However, the PFS benefit was not determined to be significant, at 2.0 months and 1.8 months, respectively (HR, 0.57; 95% CI, 0.47-0.70; P <.0001).
“We now have options. I can remember a time where we really only had 1 line of therapy and now we are talking about multiple lines of therapy, multiple different options, that can be then tailored to the individual patient,” Mulcahy said. “Certainly, this agent is an option in later lines of therapy, namely third line or later.”
In the phase 3 CheckMate 577 trial (NCT02743494), patients with resected stage II/III esophageal or GEJ cancer who received neoadjuvant chemoradiation and had residual pathologic disease were randomized 2:1 to receive either nivolumab (n=532) or placebo (n=262), followed by nivolumab or placebo.14
(n=262), followed by nivolumab or placebo.14 “About 30% had squamous cell carcinoma and about 60% had adenocarcinoma,” Mulcahy noted. “The majority of patients had a PD-L1 expression of less than 1%, so we can think of the results that we see from this study as independent from what their PD-L1 expression is.”
The primary end point was disease-free survival (DFS), and secondary end points included OS and OS rate at 1, 2, and 3 years. Results showed that the median DFS with nivolumab was 22.4 months (95% CI, 16.6-34.0) versus 11.0 months (95% CI, 8.3-14.3) with placebo (HR, 0.69; 95% CI, 0.56-0.86; P=.0003).
“This is really the first study that has the most robust data we have showing any benefit with adjuvant therapy after resection for esophageal cancer,” Mulcahy said. “It potentially establishes adjuvant nivolumab as a new standard of care.”
“We certainly know that for frontline therapy, immune checkpoint inhibitors can be considered,” Denlinger concluded. “Trastuzumab deruxtecan after trastuzumab-based frontline therapy is now an option for HER2-positive disease. …Now we have multiple options in second or later lines of therapy for refractory disease. So, we can tailor our treatment regimens, not only to the particular disease characteristics but also to our patient characteristics. This is really an exciting time for this particular disease.”
1. Denlinger CS, Matkowskyj KA, Mulcahy MF, et al. NCCN guidelines updates: gastric and esophageal cancers. Presented at: NCCN 2021 Virtual Annual Conference; March 18-20, 2021.
2. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/ esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31(suppl 4):S1191. doi:10.1016/j.annonc.2020.08.2296
3. Kato K, Sun JM, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31(suppl 4):S1192-S1193. doi:10.1016/j.annonc.2020.08.2298
4. Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-2049. doi:10.1200/JCO.2013.53.6136
5. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640-653. doi:10.1016/S1470-2045(17)30111-0
6. Makiyama A, Sagara K, Kawada J, et al. A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). J Clin Oncol. 2018;36(suppl 15):4011. doi:10.1200/JCO.2018.36.15_suppl.4011
7. Shitara K, Bang YJ, Iwasa S, et al; DESTINY-Gastric01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413
8. Lorenzen S, Thuss-Patience PC, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: results from the phase II RAMIRIS study of the AIO. J Clin Oncol. 2020;38(suppl 15):4514. doi:10.1200/ JCO.2020.38.15_suppl.4514
9. . Fuchs CS, Ozguroglu M, Bang YJ, et al. Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: phase 3 KEYNOTE-061 trial. J Clin Oncol. 2018;36(suppl 15):4062. doi:10.1200/JCO.2018.36.15_suppl.4062
10. Shitara K, Ozhuroglu M, Bang YJ, et al; KEYNOTE-061 Investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-133. doi:10.1016/S0140-6736(18)31257-1
11. . Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013
12. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437-1448. doi:10.1016/S1470-2045(18)30739-3
13. Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial. JAMA Oncol. 2019;6(1):e193531. doi:10.1001/jamaoncol.2019.3531
14. A Oncol. 2019;6(1):e193531. doi:10.1001/jamaoncol.2019.3531 14. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the CheckMate 577 study. Ann Oncol. 2020;31(suppl 4):S1193-S1194. doi:10.1016/j. annonc.2020.08.2299